AMAG Pharmaceuticals (AMAG) Given Daily Coverage Optimism Rating of 0.27

News stories about AMAG Pharmaceuticals (NASDAQ:AMAG) have been trending positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AMAG Pharmaceuticals earned a news sentiment score of 0.27 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 44.6487338253249 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:

Shares of AMAG Pharmaceuticals (NASDAQ AMAG) traded up $0.65 during mid-day trading on Friday, hitting $12.95. The stock had a trading volume of 2,352,849 shares, compared to its average volume of 964,935. The stock has a market cap of $456.98, a P/E ratio of -2.13 and a beta of 0.79. AMAG Pharmaceuticals has a fifty-two week low of $11.93 and a fifty-two week high of $25.20. The company has a current ratio of 1.59, a quick ratio of 1.48 and a debt-to-equity ratio of 0.94.

AMAG has been the subject of several analyst reports. Zacks Investment Research downgraded AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. B. Riley reaffirmed a “hold” rating and set a $16.00 price objective on shares of AMAG Pharmaceuticals in a research note on Tuesday, January 16th. Janney Montgomery Scott reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Tuesday, October 17th. Morgan Stanley reduced their price objective on AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating for the company in a research note on Friday, November 3rd. Finally, Piper Jaffray Companies reissued a “hold” rating and set a $15.00 target price on shares of AMAG Pharmaceuticals in a research note on Thursday, January 18th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the company. AMAG Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $19.89.

ILLEGAL ACTIVITY NOTICE: “AMAG Pharmaceuticals (AMAG) Given Daily Coverage Optimism Rating of 0.27” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/02/11/amag-pharmaceuticals-amag-given-daily-coverage-optimism-rating-of-0-27.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Insider Buying and Selling by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit